Changes in Beneficial Ownership · 4
Scribe Therapeutics Inc.
SCTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-27
- Issuer
- Scribe Therapeutics, Inc.
- Issuer CIK
- 0001853921
- Trading symbol
- SCTX
Reporting owner 1
- Name
- ORBIMED ADVISORS LLC
- Reporting owner CIK
- 0001055951
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022
Reporting owner 2
- Name
- OrbiMed Capital GP VIII LLC
- Reporting owner CIK
- 0001845804
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022-4629
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-27 | C · Form 4 | 348,825 | A | [F1] | 348,825 | I | See footnotes[F3][F4] |
| Common Stock | 2026-07-27 | P · Form 4 | 1,000,000[F2] | A | 15 | 1,348,825 | I | See footnotes[F3][F4] |
Table key
- C · Form 4
- Derivative conversion
- A
- Acquired
- I
- Indirect
- P · Form 4
- Purchase on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock | [F1] | 2026-07-27 | C · Form 4 | 2,065,672 | D | 0 | [F1] | [F1] | Common Stock | 348,825 | 0 | I | See footnotes[F3][F4] |
Table key
- C · Form 4
- Derivative conversion
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.↩ 1↩ 2↩ 3↩ 4
- F2
- Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.↩ 1
- F3
- The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.↩ 1↩ 2↩ 3
- F4
- This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1↩ 2↩ 3
Signature 1
- Signed
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Date
- 2026-07-29
Signature 2
- Signed
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VIII LLC
- Date
- 2026-07-29
Company context
We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes. STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape. We have secured regulatory clearance from the Australian Therapeu